Plasma Fractionation Companies Strategic Expansion Initiatives, Revenue Diversification, Strategic Joint Ventures, Licensing and Monetization, Peer Comparison Analysis, Leadership and Governance

Plasma Fractionation Manufacturers and Market Growth

The global plasma fractionation market size was estimated at US$ 32.75 billion in 2023 and is projected to grow to US$ 72.86 billion by 2034, rising at a compound annual growth rate (CAGR) of 7.54% from 2024 to 2034.

Top Companies in Plasma Fractionation Market

• Syntegon
• CSL Behring
• Grifols Therapeutics
• Mitsubishi Tanabe
• Octapharma AG
• Hualan Bio
• Kedrion S.p.A
• Takeda Pharmaceutical Company Ltd.
• LFB Group
• Intas Pharmaceuticals Ltd.
• Biotest AG
• Bio Product Laboratory Ltd.

Latest Announcements by Industry Leaders

• In July 2024, Spanish drugmaker Grifols, known for its plasma-derived medicines, announced Rahul Srinivasan as its new Chief Financial officer. He appreciates this new work post and thanks Nachi Abia the CEO of Grifols he states,” the Board of the venerable institution that has made a huge difference to people’s lives with its portfolio of life-changing medicines across a wide arrange of therapeutic areas.”
• In June 2024, Roland Wandeler, President of Grifols Biopharma Business Unit comments on Biotest’s Yimmungo, “the Yimmungo will provide a strong portfolio of intravenous and subcutaneous immunoglobulins provides another innovative treatment option for patients with primary immunodeficiencies who reply of these essential medicines in their daily lives.”

Recent Developments

• In August 2024, Nanoform Finland, the medicine performance-enhancing company is developing pre-clinical plasma-derived therapies with Takeda Pharmaceutical Company. The aim is to develop plasma-derived therapy formulations for the treatment of rare conditions.
• In September 2024, GEFD – a joint venture between Grifols and Egypt’s National Service Project Organisation (NSPO) launched a project as a national initiative to achieve self-sufficiency in plasma-derived medicine, which is a vital treatment extracted from blood plasma for various medical conditions. The project includes a plasma laboratory, plasma warehouse, 20 donation centres and a state-of-art manufacturing facility.

If you have any questions, please feel free to contact us at sales@towardshealthcare.com